article thumbnail

Understanding the Regulatory Environment in Japan for Generic Drug Development

Drug Patent Watch

The regulatory environment in Japan for generic drug development is complex and has undergone significant changes in recent years. New Drug Application (NDA) : Needed for marketing approval of new drugs. Abbreviated New Drug Application (ANDA) : Required for marketing approval of generic drugs.

article thumbnail

Driving change: Digital innovation and the future of drug discovery in India

Express Pharma

It places way more emphasis on hands- on training for pharmaceutics, medicinal chemistry, and pharmaceutical analysis while sidelining practicals in foundational sciences like human anatomy, physiology, patho- physiology, and clinical pharmacology. The collab- oration between industry and academia in drug development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Issues “Cliffs Notes”-style Guidance on Cell and Gene Therapy; What Questions Did They Answer? (Part 1)

FDA Law Blog: Biosimilars

The draft guidance includes FAQs covering topics from across disciplines: regulatory review; chemistry, manufacturing, and controls (CMC); nonclinical and pharmacology/toxicology (PT); clinical; and clinical pharmacology.

article thumbnail

Zydus receives USFDA approval to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS

Express Pharma

1162 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Three Patients with Cryopyrin-Associated Periodic Syndromes, Clinical Pharmacology in Drug Development, 2023, 0(0) 18. DOI: 10.1002/cpdd.1162 DOI: 10.1002/cpdd.1318.

article thumbnail

FDA Issues Guidance on Clinical Pharmacology for Peptide Drugs

PharmaTech

The guidance document discusses the impact of clinical pharmacology considerations on peptide drug development.

article thumbnail

Zydus begins Phase II trial of ZYIL1, NLRP3 inhibitor in patients with ALS

Express Pharma

Zydus has established the Phase 2 proof-of-concept in CAPS patients [NCT05186051] and has now published the data in Clinical Pharmacology in Drug Development. In Phase I studies, ZYIL1 was found to be safe and well-tolerated [NCT04731324, NCT04972188].

article thumbnail

Translating complex data into actionable insights, to create big value for smaller biotech companies

BioPharma Dive

Why clinical pharmacology is critical to accelerating drug development, and how it can help drive value in a complex and rapidly evolving landscape.